Study Shows Varied Results from Different Methods of Measuring Albumin
By LabMedica International staff writers Posted on 21 Feb 2017 |

Image: A structural model of serum albumin (Photo courtesy of Wikimedia Commons).
A recent paper compared the accuracy of several different methods for determining levels of serum or plasma albumin, measurements, which are used to evaluate the nutritional status, kidney function, and fluid balance of dialysis patients.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Latest Clinical Chem. News
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
- Simple Urine Test Could Detect Multiple Cancers at Early Stage
- Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules
- First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns
- Paper-Based Devices Outperform Existing Methods in Diagnosing Asymptomatic Malaria
- Simple Skin Test Could Revolutionize Diagnosis of Pediatric Eosinophilic Esophagitis
- Portable Diagnostic Tool Uses Bioluminescence to Detect Viruses at POC
- AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Channels
Molecular Diagnostics
view channel
Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more
New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
Cardiometabolic diseases, which affect the heart, blood vessels, and the body's ability to process food and generate energy, are difficult to diagnose early due to the complex genetic changes that contribute... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Accurately Determines Breast Cancer Prognosis
A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. The research, published in the journal Patterns,... Read more
Powerful New Tool Improves Tissue Cancer Analysis
Studying the mix of cell types in human tissue is crucial for understanding diseases like cancer, but it presents significant challenges in both accuracy and scalability. The tumor microenvironment, composed... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more